A Phase III, Open-label, Multi-Center Study to Evaluate the long term Safety of nemolizumab in Japanese Atopic Dermatitis Patients with moderate to severe pruritus

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2080223838

Enrollment

Registered

2018-03-13

Start date

2018-03-20

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atopic dermatitis with pruritus who are inadequately controlled by existing therapies

Interventions

investigational material(s) Generic name etc : nemolizumab INN of investigational material : nemolizumab Therapeutic category code : 449 Other antiallergic agents Dosage and Administration for Investi

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Atopic Dermatitis with moderate or severe pruritus patients

Exclusion criteria

Exclusion criteria: - Patients with body weight <30.0kg - Patients with Hepatitis B virus or hepatitis C virus infection - Patients with Evidence of tuberculosis (TB) infection - Patients with immune deficiency - Pregnant or lactating women

Design outcomes

Primary

Measure	Time frame
safety Safety assessmemt Adverse event/Laboratory tests/Vital signs/ECG	—

Secondary

Measure	Time frame
efficacy pruritus Visual Analogue Scale(VAS) Patients will assess pruritus Visual Analogue Scale(VAS)	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026